Register for the ECTRIMS-ACTRIMS Patient Community Day to engage with MS research experts in Toronto or online, October 2026.

The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) will host its ninth annual meeting in West Palm Beach, Florida, from February 29 to March 2, 2024, to address a ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The second annual stand-alone meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) will be offering cutting-edge research in the same warm locale that is home ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Read about the diverse array of research presented at this year's meeting, including novel technological advancements and insights into disease progression in multiple sclerosis (MS). Our top coverage ...

CAMBRIDGE, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data underscoring the efficacy and safety of its broad, industry-leading portfolio of multiple ...

Vidofludimus Calcium's Activation of Nurr1 Reduces Neuronal Loss and Injury Directly and Indirectly By Decreasing Microglial Activations in Preclinical Models Top-Line Data from Phase 2 CALLIPER Trial ...

Research findings from Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023 provide updates on MS diagnosis and treatment. Research presented at the Americas ...

SAN DIEGO — The third annual forum of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), to be held here February 1 through 3, will offer cutting-edge research and ...

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the phase II ...

New data from ongoing Phase 3 study further define the effectiveness and improved GI tolerability of VUMERITY® (diroximel fumarate) Real-world findings evaluate quality of life benefits associated ...